Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBITDA Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBITDA Margin for 13 consecutive years, with 80.05% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 12910.0% to 80.05% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 74.97% through Dec 2025, up 15260.0% year-over-year, with the annual reading at 3.35% for FY2025, 6957.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 80.05% at Theravance Biopharma, up from 18.29% in the prior quarter.
  • The five-year high for EBITDA Margin was 7361.3% in Q3 2022, with the low at 1038.96% in Q1 2022.
  • Average EBITDA Margin over 5 years is 200.01%, with a median of 84.27% recorded in 2024.
  • The sharpest move saw EBITDA Margin skyrocketed 762886bps in 2022, then crashed -741794bps in 2023.
  • Over 5 years, EBITDA Margin stood at 375.8% in 2021, then soared by 68bps to 119.0% in 2022, then surged by 70bps to 35.53% in 2023, then tumbled by -38bps to 49.06% in 2024, then skyrocketed by 263bps to 80.05% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 80.05%, 18.29%, and 209.3% for Q4 2025, Q3 2025, and Q2 2025 respectively.